| Indication | Oncology |
| Status | ‒ ODD granted on December 23th, 2020.
‒ PK studies ongoing. |
| Product Advantages | Handa is utilizing its ONCORE™ technology to develop improved versions of Oncology drug for reducing the risk associated with sever side effect and improve bioavailability. |
| Potential Market | According to the data in 2024 annual report of the brand company, the total sales of the brand drug were approximately US$1.671 billion. |
?
R&D
HND-027
